公开(公告)号：US20160039821A1

公开(公告)日：2016-02-11

申请号：US14774866

申请日：2014-03-12

Applicant: ABBVIE INC.

Inventor： Steven D. Fidanze ,  Dachun Liu ,  Robert A. Mantei ,  Keith F. McDaniel ,  John Pratt ,  George S. Sheppard ,  Le Wang ,  Andrew Bogdan ,  James H. Holms ,  Justin D. Dietrich ,  Jasmina Marjanovic ,  Lisa A. Hasvold ,  Yujia Dai

IPC: C07D471/22 ,  C07D471/16

CPC classification number: C07D471/22 ,  C07D471/16

Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y2, Y3, A1, A2, A3 and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

Abstract translation: 本发明提供式（I）化合物，其中R1，R2，R6，Y1，Y2，Y3，A1，A2，A3和A4具有说明书中定义的任何值及其药学上可接受的盐，其是有用的 作为治疗疾病和病症的药剂，包括炎性疾病，癌症和AIDS。 还提供了包含一种或多种式（I）化合物的药物组合物。

公开(公告)号：US20140275026A1

公开(公告)日：2014-09-18

申请号：US14206028

申请日：2014-03-12

Applicant: AbbVie Inc.

Inventor： Le Wang ,  John Pratt ,  Lisa A. Hasvold ,  Dachun Liu ,  Yujia Dai ,  Steven D. Fidanze ,  James H. Holms ,  Robert A. Mantei ,  Keith F. McDaniel ,  George S. Sheppard ,  William J. McClellan

IPC: C07D471/04

CPC classification number: C07D471/04 ,  C07D519/00

Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, and R5 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

Abstract translation: 本发明提供式（I）化合物，其中R 1，R 2，R 3，R 4和R 5具有说明书中定义的任何值及其药学上可接受的盐，其可用作治疗疾病和病症的试剂 ，包括炎性疾病，癌症和艾滋病。 还提供了包含一种或多种式（I）化合物的药物组合物。

公开(公告)号：US20130303547A1

公开(公告)日：2013-11-14

申请号：US13944447

申请日：2013-07-17

Applicant: AbbVie Inc.

Inventor： Brian E. Green ,  David D. Anderson ,  Todd D. Bosse ,  Curt S. Cooper ,  Larry L. Klein ,  Allan C. Krueger ,  Daniel P. Larson ,  Dachun Liu ,  Keith F. McDaniel ,  Christopher E. Motter ,  John K. Pratt ,  Todd W. Rockway ,  Teresa A. Rosenberg ,  Ming C. Yeung ,  Hui-Ju Chen ,  Jason P. Shanley

IPC: C07D403/12 ,  C07D409/14 ,  C07D403/14 ,  C07D207/16 ,  C07D241/24

CPC classification number: C07D403/12 ,  C07D207/16 ,  C07D241/24 ,  C07D403/14 ,  C07D409/14 ,  C07K7/02

Abstract: This invention relates to: (a) compounds of formula I and salts thereof that, inter alia, are useful as hepatitis C virus (HCV) inhibitors; (b) intermediates useful for the preparation of such compounds and salts; (c) pharmaceutical compositions comprising such compounds and salts; and (d) methods of use of such compounds, salts, and compositions.

Abstract translation: 本发明涉及：（a）式I化合物及其盐，其特别可用作丙型肝炎病毒（HCV）抑制剂; （b）可用于制备这些化合物和盐的中间体; （c）包含这些化合物和盐的药物组合物; 和（d）使用这些化合物，盐和组合物的方法。

公开(公告)号：US20250152600A1

公开(公告)日：2025-05-15

申请号：US18742823

申请日：2024-06-13

Applicant: AbbVie Inc.

Inventor： Le Wang ,  John K. Pratt ,  Keith F. McDaniel ,  Steven D. Fidanze ,  Lisa Hasvold ,  James H. Holms ,  Warren M. Kati ,  Dachun Liu ,  Robert A. Mantei ,  William J. McClellan ,  George S. Sheppard ,  Carol K. Wada ,  Yujia Dai

IPC: A61K31/541 ,  A61K31/437 ,  A61K31/5025 ,  A61K31/5377 ,  A61K45/06 ,  C07D471/04 ,  C07D487/04

Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

公开(公告)号：US20190008866A1

公开(公告)日：2019-01-10

申请号：US16117203

申请日：2018-08-30

Applicant: AbbVie Inc.

Inventor： Andrew Bogdan ,  Warren M. Kati ,  Keith F. McDaniel ,  Chang H. Park ,  George S. Sheppard ,  Le Wang

IPC: A61K31/506 ,  C07D487/04 ,  A61K31/4412 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/497 ,  C07D211/86 ,  C07D213/69 ,  C07D401/04 ,  C07D401/12 ,  C07D405/04 ,  C07D405/12 ,  C07D413/12 ,  C07D417/04 ,  A61K31/444 ,  C07D417/12

Abstract: The present invention provides for compounds of formula (I) wherein Y1, Y2, R1, R2, R3, A1, A2, A3, and A4, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

公开(公告)号：US20180298003A1

公开(公告)日：2018-10-18

申请号：US16018357

申请日：2018-06-26

Applicant: AbbVie Inc.

Inventor： Steven D. Fidanze ,  Dachun Liu ,  Robert A. Mantei ,  Keith F. McDaniel ,  John Pratt ,  George S. Sheppard ,  Le Wang ,  Andrew Bogdan ,  James H. Holms ,  Justin D. Dietrich ,  Jasmina Marjanovic ,  Lisa A. Hasvold ,  Yujia Dai

IPC: C07D471/22 ,  C07D471/16

Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y2, Y3, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

公开(公告)号：US20180296566A1

公开(公告)日：2018-10-18

申请号：US16012379

申请日：2018-06-19

Applicant: AbbVie Inc.

Inventor： Le Wang ,  John K. Pratt ,  Keith F. McDaniel ,  Yujia Dai ,  Steven D. Fidanze ,  Lisa Hasvold ,  James H. Holms ,  Warren M. Kati ,  Dachun Liu ,  Robert A. Mantei ,  William J. McClellan ,  George S. Sheppard ,  Carol K. Wada

IPC: A61K31/541 ,  A61K45/06 ,  C07D487/04 ,  C07D471/04 ,  A61K31/5025 ,  A61K31/437 ,  A61K31/5377

Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

公开(公告)号：US10085985B2

公开(公告)日：2018-10-02

申请号：US15216855

申请日：2016-07-22

Applicant: AbbVie Inc.

Inventor： Andrew Bogdan ,  Warren M. Kati ,  Keith F. McDaniel ,  Chang H. Park ,  George S. Sheppard ,  Le Wang

IPC: A61K31/506 ,  C07D487/04 ,  C07D211/86 ,  C07D405/04 ,  C07D401/04 ,  C07D417/04 ,  C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D213/69 ,  A61K31/4412 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/497

Abstract: The present invention provides for compounds of formula (I) wherein Y1, Y2, R1, R2, R3, A1, A2, A3, and A4, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

公开(公告)号：US20160331749A1

公开(公告)日：2016-11-17

申请号：US15216855

申请日：2016-07-22

Applicant: AbbVie Inc.

Inventor： Andrew Bogdan ,  Warren M. Kati ,  Keith F. McDaniel ,  Chang H. Park ,  George S. Sheppard ,  Le Wang

IPC: A61K31/506 ,  A61K31/4433 ,  A61K31/497 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/4412 ,  A61K31/4439

CPC classification number: A61K31/506 ,  A61K31/4412 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/497 ,  C07D211/86 ,  C07D213/69 ,  C07D401/04 ,  C07D401/12 ,  C07D405/04 ,  C07D405/12 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D487/04

Abstract: The present invention provides for compounds of formula (I) wherein Y1, Y2, R1, R2, R3, A1, A2, A3, and A4, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Abstract translation: 其中Y1，Y2，R1，R2，R3，A1，A2，A3和A4具有说明书中定义的任何值及其药学上可接受的盐，其可用作治疗疾病和病症的试剂，包括 炎性疾病，癌症和艾滋病。 还提供了由一种或多种式（I）化合物组成的药物组合物。

公开(公告)号：US09493506B2

公开(公告)日：2016-11-15

申请号：US14299095

申请日：2014-06-09

Applicant: Enanta Pharmaceuticals, Inc. ,  AbbVie, Inc.

Inventor： Hui-Ju Chen ,  Keith F. McDaniel ,  Brian E. Green ,  Jason P. Shanley ,  Albert W. Kruger ,  Jorge Gandarilla ,  Dennie S. Welch ,  Russell D. Cink ,  Steven C. Cullen ,  Yonghua Gai ,  Guoqiang Wang ,  Yat Sun Or

IPC: C07D487/04 ,  C07K5/083

CPC classification number: C07K5/081 ,  C07D487/04

Abstract: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.